# UroGen Pharma (URGN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/URGN
## Company Profile
- Ticker: URGN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel with U
- Tags: Oncology
## Stock Data
- Close: 47.11 USD
- Market cap: 1293073944.54 USD
- Last updated: 2026-08-11
## Business Overview
### Uro-Oncology Franchise
UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease.
### Commercial ZUSDURI Platform
ZUSDURI is FDA approved for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin product uses UroGen’s RTGel technology and anchors the company’s commercial presence in bladder cancer.
### Next-Generation Mitomycin Programs
UGN-103 is a next-generation mitomycin formulation for recurrent low-grade intermediate-risk NMIBC and is advancing toward an NDA based on the Phase 3 UTOPIA trial. UGN-104 applies a related formulation strategy to low-grade upper tract urothelial carcinoma and is being studied in an ongoing Phase 3 trial.
### Oncolytic Virus Expansion
UGN-501 is an investigational next-generation oncolytic virus initially planned for intravesical administration in NMIBC. The company also intends to evaluate delivery with RTGel, potentially extending local exposure and activity.
## Why The Stock Is Moving

As of Aug 11, 2026, URGN closed up 1.73% at $47.11. No new same-company headline was identified in the current news window.

## Future Catalysts

- Six-month durability data for UGN-103 expected in mid-2026.
- UGN-501 IND submission planned for the second quarter of 2026, followed by Phase 1 initiation by year-end.
- UGN-103 NDA submission planned for the second half of 2026.
- Completion of enrollment in the UGN-104 Phase 3 trial expected by year-end 2026.

## Drug Assets

- ZUSDURI

## Recent News
- 2026-08-05 12:00 EST — [UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights](https://biopharmsignal.com/news/URGN/urogen-reports-50-4-million-of-zusduri-revenue-and-provides-second-quarter-2026--d8903f44) — Source: UroGen Pharma
- 2026-07-29 12:00 EST — [UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026](https://biopharmsignal.com/news/URGN/urogen-pharma-to-report-second-quarter-2026-financial-results-on-wednesday-augus-bbf2c6c0) — Source: UroGen Pharma
- 2026-07-15 12:00 EST — [UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103](https://biopharmsignal.com/news/URGN/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-jul-c474cf91) — Source: UroGen Pharma
- 2026-07-08 12:00 EST — [UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer](https://biopharmsignal.com/news/URGN/urogen-announces-fda-clearance-of-the-ind-for-ugn-501-an-investigational-next-ge-1733c603) — Source: UroGen Pharma
- 2026-06-05 12:00 EST — [UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/URGN/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-c57d219f) — Source: UroGen Pharma